China'S Advanced Path In Biomedicine: Innovation Is Coming, And High Quality Development Is About To Open.

In December 27, 2019, only four days from 2020, China's market for innovative drugs ushered in 3 heavy varieties: the injection of ralazolam, the injection of retoluzumab, the injection of ralezumab, and the drug of Paley, the second drug of toluene sulphonate.

In November 3, 2019, at the China Biotechnology Innovation Conference, the Ministry of science and technology of the Ministry of social development and technology and the China Biotechnology Development Center released a report showing that in 2018, the scale of the bio pharmaceutical industry in China has exceeded 350 billion yuan, and a total of 9 newly developed 1 NEW drugs have been approved for sale.

This year, encouraging biopharmaceutical companies to list is a major event in the capital market. Li Kang, an audit services partner of Ernst & young, pointed out that whether it is the science innovation board or the operation of the listed companies, we can see that the high-quality Biopharmaceutical Enterprises are developing rapidly. "Biopharmaceutical and even innovative pharmaceutical companies will be the focus of capital attention for a long time." In 2019, 8 Chinese biopharmaceutical companies raised $2 billion 300 million through the IPO of the Hongkong exchange, almost 10 times the amount raised by European companies during the same period.

This is only a microcosm of the advanced development of Chinese biomedicine.

In recent years, the restructuring and establishment of the national health insurance agency and the encouragement of innovative drug policy intensive publications have promoted the development of Chinese bio medicine.

For example, the opinions issued by the general office of the State Council on deepening the reform of the examination and approval system and encouraging the innovation of pharmaceutical and medical devices will not only play a great role in encouraging the innovation subjects, but also play a key role in the integration of new drug research and development with the international practice.

The relevant policy release has also made great progress in the reform of clinical trial management, and promoted the development of new drug listing in China. It has changed the qualification system of clinical trial institutions into a record management system, which has solved the contradiction of insufficient clinical resources. The application of clinical trials has been changed from the examination and approval system to the default licensing system, which ensures the rights and interests of registered applicants.

At the same time, Xu Jiaxi of Xingye Securities pointed out that under the impact of the quantity purchase, the original sales mode of the generic drug companies has gradually changed, and expanding the incremental varieties including innovative drugs has become an inevitable choice for enterprises to face the impact of the policy. Under the joint driving of policies, capital and talents, the domestic innovation medicine sector will still maintain a relatively high boom.

And the national health insurance agency has adjusted the medical insurance directory dynamically, and has carried out national health insurance negotiations.

In the view of Liu Min, chief business officer of XinDa, the national health insurance negotiations have great significance for innovative enterprises including XinDa biology, and also help to adjust the structure of China's pharmaceutical industry and promote the transformation and upgrading of the national pharmaceutical industry.

Ding Da Ming, chairman of Beida pharmaceutical company, pointed out to the twenty-first Century economic news reporter that innovative drugs can enter the medical insurance catalog in time, and enter the hospital directly affect the survival of pharmaceutical companies, as well as follow-up R & D investment and innovation.

Shi Lichen, head of Beijing Ding Chen medical management consulting center, believes that the change of policy is forcing bio medicine enterprises to accelerate innovation and research and development. "The current trend is that more and more pharmaceutical companies are innovating and competition is more intense. If enterprises do not increase R & D investment in a timely manner, they will face the risk of being eliminated by the market."

According to Frost&Sullivan analysis, drug R & D expenditure in China has been increasing year by year in recent years, and the growth rate is expected to remain above 20% in 2019-2023 years.

According to another data, from 2015 to 2018, the total R & D expenses of Heng Rui pharmaceutical were 890 million yuan, 1 billion 180 million yuan, 1 billion 750 million yuan, and 2 billion 670 million yuan respectively; the total R & D expenses of Fuxing medicine were 830 million yuan, 1 billion 100 million yuan, 1 billion 530 million yuan and 2 billion 500 million yuan; the total R & D expenses of Shanghai medicine were 620 million yuan, 670 million yuan, 836 million yuan, and 836 million yuan.

However, according to the data of Guangzhou punctuation medical information Limited (PICO), the R & D investment of pharmaceutical enterprises in China accounts for only 6% of the world's total, far from the US, and there is a big gap between R & D investment of Chinese enterprises and international enterprises. The Research Report of global innovation 1000 released by PWC (PwC) shows that Roche's R & D expenditure in 2017 was US $11 billion 800 million, and in 2018 it was US $10 billion 800 million, ranking first in the pharmaceutical, biotechnology and life sciences fields. The R & D expenditure of Johnson in 2017 was US $9 billion 100 million and 2018 was US $10 billion 600 million; the development expenditure of Merck in 2018 in 2018 was US $10 billion 200 million.

"To innovate and develop Chinese medicine, enterprises need to persist in R & D investment. China's big power enterprises should take corresponding responsibilities, increase R & D investment and support innovation and development." Shi Lichen pointed out.